60 minutes
In 2012, Nature famously published a review by a former Amgen head of oncology research that 90% of landmark studies could not be reproduced. Company founders and initial investors must be certain that the academic work underpinning the foundational science and licensed patents are grounded in a sufficiently robust body of multiple lines of evidence can be reproduced. Serial founders and prolific professors discuss how to be sure initial scientific results are both fundable and can be advanced to "pharma grade".


Abi Barrow - Managing Partner, Cambridge Innovation Partners
Irena Ivanovska - Boston Site Head and Director, Celdara Medical
Irene Abrams - Vice President, Technology Development and New Ventures, Boston Children's Hospital
Issi Rozen - CBO, Broad Institute of MIT and Harvard
Name Audience
Science Track